Stocks Health care CLOV
NASDAQ · Health careClover Health Investments, Corp. (CLOV)
Clover Health Investments, Corp. brought in $2.7B of revenue over the twelve months to September 30, 2026, up 54.5% from a year earlier. Net income was $12.5M, a net margin of 0.5%. In fiscal 2025 capital spending exceeded operating cash flow by $69M. At September 30, 2026 it held $268.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Clover Health Investments, Corp.
- Net worth
- Clover Health Investments, Corp. has a market value (market cap) of $2.6B at the latest share price, and shareholders' equity of $390.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.9B (+40.3% year on year), with a net loss of $85.5M. Over the 12 months to September 30, 2026: revenue $2.7B, net income $12.5M.
- Cash flow
- In fiscal 2025 operations used $66.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Clover Health Investments, Corp.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Clover Health Investments, Corp. does
Clover Health Investments, Corp. is registered with the SEC under industry code SIC 6324 (Hospital & Medical Service Plans). Its shares trade on NASDAQ under the ticker CLOV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.9B | -$85.5M | n/a | -$69M |
| 2024 | $1.4B | -$43M | n/a | $33.3M |
| 2023 | $1.3B | -$213.4M | -$0.44 | -$145.2M |
| 2022 | $1.1B | -$339.6M | -$0.71 | -$208.4M |
| 2021 | $1.5B | -$587.8M | -$1.42 | -$283M |
| 2020 | $672.9M | -$136.4M | -$1.54 | -$119.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CLOV ranks in Health care
Latest SEC filings
What Clover Health Investments, Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 53% to $759.3M versus the same quarter last year; diluted EPS $0.01 versus -$0.05.
- November 4, 2026
- October 9, 2026
- September 25, 2026Executive or director change8-K/AClover Health appointed Senator Robert G. Torricelli and Dr. Brian J. Miller to its Board of Directors.
- September 24, 2026Executive or director change8-KClover Health appointed former Senator Robert Torricelli and Dr. Brian J. Miller to its Board of Directors.
- August 20, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 56% to $743.2M versus the same quarter last year; diluted EPS $0.05 versus -$0.02.
- August 5, 2026
- July 17, 2026Other event 8-K
- June 18, 2026Other event 8-K
Insider trades
What the people running Clover Health Investments, Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.8M worth of shares in the last 90 days and bought none on the open market. Most of the selling (97%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Thornton Joseph ClayChief Financial Officer | Received as pay | 328,947 | - |
| November 4, 2026 | Oldakowski Joseph FrankChief Accounting Officer | Received as pay | 186,403 | - |
| October 20, 2026 | Soares KarenChief Legal Officer | Soldpre-planned (10b5-1) | 19,275 | $89.8K |
| October 19, 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Soldpre-planned (10b5-1) | 4,066 | $17.9K |
| October 15, 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Soldpre-planned (10b5-1) | 18,273 | $85.5K |
| October 15, 2026 | Wai ConradCEO, Counterpart Health | Soldpre-planned (10b5-1) | 23,627 | $110.6K |
| October 15, 2026 | Thornton Joseph ClayInterim CFO | Soldpre-planned (10b5-1) | 4,591 | $21.5K |
| October 15, 2026 | Soares KarenChief Legal Officer | Soldpre-planned (10b5-1) | 14,673 | $68.7K |
Who owns CLOV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 225 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 35,106,965 | +3,266,453 |
| Vanguard Capital Management LLC | 18,037,661 | +1,055,588 |
| Geode Capital Management, LLC | 10,846,066 | +790,556 |
| State Street Corp | 10,180,337 | +620,448 |
| Nuveen, LLC | 6,291,699 | +5,356,156 |
| Charles Schwab Investment Management Inc | 5,521,188 | +220,713 |
| Vanguard Portfolio Management LLC | 4,470,452 | +774,015 |
| Northern Trust Corp | 3,772,600 | +466,025 |
| PNC Financial Services Group, Inc. | 3,563,874 | -200,160 |
| Dimensional Fund Advisors LP | 3,148,626 | -269,240 |
| Vanguard Fiduciary Trust Co | 2,919,893 | +113,683 |
| Renaissance Technologies LLC | 2,807,441 | -594,100 |
| Morgan Stanley | 2,294,305 | +107,881 |
| Citadel Advisors LLC | 2,163,205 | +285,157 |
| D. E. Shaw & Co., Inc. | 1,965,493 | +1,874,482 |
| Marshall Wace, Llp | 1,563,189 | new |
| Invesco Ltd. | 1,336,790 | +308,419 |
| GMT Capital Corp | 1,305,200 | 0 |
| Mackenzie Financial Corp | 1,297,476 | new |
| Jane Street Group, LLC | 1,291,443 | +250,039 |
Insiders
16 insiders reported holding 29,721,502 shares in total, about $146.5M at the last price.
| Holder | Shares |
|---|---|
| Toy AndrewChief Executive Officer, Director | 9,078,334 |
| Kuipers Peter J.Chief Financial Officer | 5,758,353 |
| Reynoso Jamie L.CEO, Medicare Advantage | 2,770,351 |
| Wai ConradCEO, Counterpart Health | 2,212,1281,170,056 held indirectly |
| Priest Brady PatrickCEO of Clover Care Services | 2,040,222 |
| Garipalli VivekDirector, 10% owner | 1,856,247 |
| Thornton Joseph ClayChief Financial Officer | 1,573,882 |
| Soares KarenChief Legal Officer | 1,573,423 |
| Kouzoukas Demetrios L.Director | 605,980 |
| Robinson William G JrDirector | 597,987 |
Questions about CLOV
What does Clover Health Investments, Corp. do?
Clover Health Investments, Corp. is a company in the Health care sector, listed on NASDAQ as CLOV. Its shares trade on NASDAQ under the ticker CLOV.
What is Clover Health Investments, Corp.'s net worth?
Clover Health Investments, Corp. has a market value (market cap) of $2.6B at the latest share price, and shareholders' equity of $390.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Clover Health Investments, Corp. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $12.5M on revenue of $2.7B, a net margin of 0.5%.
How much revenue does Clover Health Investments, Corp. make?
Over the twelve months to September 30, 2026 Clover Health Investments, Corp. reported revenue of $2.7B. That is 54.5% more than a year earlier.
When did Clover Health Investments, Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Clover Health Investments, Corp.'s next earnings report?
Clover Health Investments, Corp.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CLOV with
Follow CLOV
Get an email when Clover Health Investments, Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Clover Health Investments, Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.